Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Trial Profile

Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Ecallantide (Primary)
  • Indications Angioedema
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Dyax; Shire
  • Most Recent Events

    • 05 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top